Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016.

Löblová O, Csanádi M, Ozierański P, Kaló Z, King L, McKee M.

Health Policy. 2019 Aug;123(8):713-720. doi: 10.1016/j.healthpol.2019.05.021. Epub 2019 Jun 8.

PMID:
31277882
2.

The whistleblowing drama behind Astellas's suspension from the ABPI.

Cohen D, Mulinari S, Ozieranski P.

BMJ. 2019 Jul 2;366:l4353. doi: 10.1136/bmj.l4353. No abstract available.

PMID:
31266743
3.

Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015.

Ozieranski P, Csanadi M, Rickard E, Tchilingirian J, Mulinari S.

JAMA Netw Open. 2019 Jun 5;2(6):e196253. doi: 10.1001/jamanetworkopen.2019.6253.

4.

Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology.

Löblová O, Csanádi M, Ozierański P, Kaló Z, King L, McKee M.

Health Policy. 2019 Jul;123(7):630-634. doi: 10.1016/j.healthpol.2019.05.012. Epub 2019 May 20.

PMID:
31130319
5.

Exposing drug industry funding of UK patient organisations.

Ozieranski P, Rickard E, Mulinari S.

BMJ. 2019 May 22;365:l1806. doi: 10.1136/bmj.l1806. No abstract available.

6.

How not to waste a crisis: a qualitative study of problem definition and its consequences in three hospitals.

Martin G, Ozieranski P, Leslie M, Dixon-Woods M.

J Health Serv Res Policy. 2019 Jul;24(3):145-154. doi: 10.1177/1355819619828403. Epub 2019 Mar 1. No abstract available.

PMID:
30823848
8.

When health technology assessment is confidential and experts have no power: the case of Hungary.

Csanádi M, Löblová O, Ozierański P, Harsányi A, Kaló Z, McKee M, King L.

Health Econ Policy Law. 2019 Apr;14(2):162-181. doi: 10.1017/S1744133118000051. Epub 2018 Mar 26.

9.

Transparency in practice: Evidence from 'verification analyses' issued by the Polish Agency for Health Technology Assessment in 2012-2015.

Ozierański P, Löblová O, Nicholls N, Csanádi M, Kaló Z, McKee M, King L.

Health Econ Policy Law. 2019 Apr;14(2):182-204. doi: 10.1017/S1744133117000342. Epub 2018 Jan 8.

10.

Wales approves new hepatitis C drug while England deliberates.

Ozieranski P, King L.

BMJ. 2016 Dec 1;355:i6499. doi: 10.1136/bmj.i6499. No abstract available.

PMID:
27908876
11.

Multimethod study of a large-scale programme to improve patient safety using a harm-free care approach.

Power M, Brewster L, Parry G, Brotherton A, Minion J, Ozieranski P, McNicol S, Harrison A, Dixon-Woods M.

BMJ Open. 2016 Sep 22;6(9):e011886. doi: 10.1136/bmjopen-2016-011886.

12.

A pill too hard to swallow: how the NHS is limiting access to high priced drugs.

Gornall J, Hoey A, Ozieranski P.

BMJ. 2016 Jul 27;354:i4117. doi: 10.1136/bmj.i4117. No abstract available.

PMID:
27469086
13.

The persistence of cliques in the post-communist state. The case of deniability in drug reimbursement policy in Poland.

Ozierański P, King L.

Br J Sociol. 2016 Jun;67(2):216-41. doi: 10.1111/1468-4446.12193. Epub 2016 May 21.

PMID:
27206533
14.

Running a hospital patient safety campaign: a qualitative study.

Ozieranski P, Robins V, Minion J, Willars J, Wright J, Weaver S, Martin GP, Woods MD.

J Health Organ Manag. 2014;28(4):562-75.

15.

Walkrounds in practice: corrupting or enhancing a quality improvement intervention? A qualitative study.

Martin G, Ozieranski P, Willars J, Charles K, Minion J, McKee L, Dixon-Woods M.

Jt Comm J Qual Patient Saf. 2014 Jul;40(7):303-10.

16.

How collaborative are quality improvement collaboratives: a qualitative study in stroke care.

Carter P, Ozieranski P, McNicol S, Power M, Dixon-Woods M.

Implement Sci. 2014 Mar 11;9(1):32. doi: 10.1186/1748-5908-9-32.

17.

Culture and behaviour in the English National Health Service: overview of lessons from a large multimethod study.

Dixon-Woods M, Baker R, Charles K, Dawson J, Jerzembek G, Martin G, McCarthy I, McKee L, Minion J, Ozieranski P, Willars J, Wilkie P, West M.

BMJ Qual Saf. 2014 Feb;23(2):106-15. doi: 10.1136/bmjqs-2013-001947. Epub 2013 Sep 9. Review.

18.

The politics of health technology assessment in Poland.

Ozieranski P, McKee M, King L.

Health Policy. 2012 Dec;108(2-3):178-93. doi: 10.1016/j.healthpol.2012.10.001. Epub 2012 Nov 3.

PMID:
23127957
19.

Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland?

Ozierański P, McKee M, King L.

Health Econ Policy Law. 2012 Apr;7(2):175-95. doi: 10.1017/S1744133111000168. Epub 2011 Aug 8.

Supplemental Content

Loading ...
Support Center